Definium Therapeutics, Inc. (DFTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Definium Therapeutics, Inc. on January 28, 2026. The report discloses corporate governance changes effective January 29, 2026, specifically regarding the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and associated compensation.
Material Changes
- Board Expansion: The Board of Directors increased its size from six (6) to seven (7) members.
- New Appointment: Roger Adsett was appointed as a director, effective January 29, 2026.
- Term: Mr. Adsett's term expires at the 2026 annual general meeting of shareholders or until a successor is elected.
Compensation and Governance Details
- Cash Compensation: Mr. Adsett will receive an annual retainer of $40,000, paid quarterly in arrears on a pro-rata basis.
- Equity Grant: Mr. Adsett received an option to purchase 50,000 common shares (Initial Option Grant) under the 2025 Equity Incentive Plan.
- Vesting Schedule: The option vests one-third on the first anniversary of the grant date, with the remainder vesting in equal monthly installments thereafter, contingent on continued service.
- Committee Assignments: Mr. Adsett was not assigned to any Board committees at the time of appointment.
Outlook and Risks
The filing contains no management commentary on business outlook, risks, contingencies, or unusual items. It is a standard disclosure of a director appointment and compensatory arrangements.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 50,000 share option granted to Roger Adsett in the referenced 2025 Equity Incentive Plan documents.
- Confirm the total number of outstanding options and shares reserved under the 2025 Equity Incentive Plan to assess dilution impact.
- Review the Company's most recent 10-Q or 10-K for current cash position and liquidity, as this 8-K does not contain financial statements.
- Check for any subsequent filings regarding Mr. Adsett's committee assignments or changes to the Board composition.